Cyto-SAT: a self-assessment tool for safe handling of cytotoxic medicines in low and middle-income countries

Objectives

Develop, validate and pilot-test a self-assessment tool for low and middle-income countries (LMIC)

- Support implementation of safe handling practices
- Promote continuous quality improvement regarding cytotoxic medicines management

Conclusion

Cyto-SAT covers the entire cytotoxic process with 134 items and 10 domains.

- Validated by a large panel of highly experienced experts in oncology pharmacy
- Showed high level of satisfaction from intended users.

Context

The rising burden of cancer in LMIC and an increasing use of chemotherapy treatments stress the need to promote and improve safe handling practices of cytotoxic medicines in those settings.

Method

2016

- Literature review
  - Draft checklist build by a steering committee

- International Expert Panel

2019

- 2-round online Delphi survey
  - Level of agreement
    - Prioritization
  - Final Consensus = ≥75% of agreement

- Pilot-Testing
  - Online questionnaire (16 Likert-type questions) after using Cyto-SAT.
  - https://datapharma.ch/cytoSAT/

Results

Delphi survey

- 27 experts
- 13 countries

- 98% (134/137) of items reached consensus regarding their content and formulation

Pilot-test

- 34 healthcare facilities
- 27 countries

- Median nb of person/assessment team = 3 (min=1; max=12)

- 96% of global satisfaction

Cyto-SAT evaluation

- Usefulness
- Applicability
- Usability
- Acceptability

Authors report no conflict of interest.

Available on www.Pharm-Ed.net

Contact: Sandrine.vongrunigen@hcuge.ch